ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 991-997

  Duan, Xiaohui ^a   Mao, Xianhai ^a   Sun, Weijia ^b  

^a HUNAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

ADAM15; Gemcitabine; MHC class I polypeptide related sequence B; PANC 1 cells; Pancreatic cancer

Indexed keywords

ADAM PROTEIN; ADAM15 PROTEIN; GEMCITABINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MHC CLASS I POLYPEPTIDE RELATED SEQUENCE B PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE REPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIATOR; MOLECULAR PATHOLOGY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84873198111     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1272     Document Type: Article

References (28)

1. Sargent M, Boeck S, Heinemann V, Jauch KW, Seufferlein T and Bruns CJ: Surgical treatment concepts for patients with pancreatic cancer in Germany - results from a national survey conducted among members of the 'Chirurgische Arbeitsgemeinschaft Onkologie' (CAO) and the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO) of the Germany Cancer Society (DKG). Langenbecks Arch Surg 396:223-229, 2011.
2. Hackert T, Buchler MW and Werner J: Surgical options in the management of pancreatic cancer. Minerva Chir 64:465-476, 2009.
3. Siegel R, Desantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241, 2012.
4. Levi F, Lucchini F, Negri E and La Vecchia C: Pancreatic cancer mortality in Europe: the leveling of an epidemic. Pancreas 27:139-142, 2003. (Pubitemid 36950725)
5. Waldmann TA: Immunotherapy: past, present and future. Nat Med 9:269-277, 2003. (Pubitemid 36362781)
6. Dranoff G: Coordinated tumor immunity. J Clin Invest 111:1116-1118, 2003. (Pubitemid 36519926)
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICB and MICB. Proc Natl Acad Sci USA 96:6879-6884, 1999. (Pubitemid 29274978)
8. Gonzalez S, Groh V and Spies T: Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298:121-138, 2006.
9. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560-568, 2004. (Pubitemid 39572106)
10. Ohashi M, Yoshida K, Kushida M, et al: Adenovirus-mediated interferon gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer 93:441-449, 2005. (Pubitemid 43080018)
11. Marten A, von Lilienfeld-Toal M, Buchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 119:2359-2365, 2006. (Pubitemid 44546956)
12. Diefenbach A, Jensen ER, Jamieson AM and Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171, 2001. (Pubitemid 32867877)
13. Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738, 2002. (Pubitemid 35177960)
14. Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67:188-195, 2006. (Pubitemid 43673929)
15. Boutet P, Aguera-Gonzalez S, Atkinson S, et al: Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182:49-53, 2009.
16. Hidalgo M: Pancreatic cancer. N Engl J Med 362:1605-1617, 2010.
17. Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915-925, 2005. (Pubitemid 40991334)
18. Li K, Mandai M, Hamanishi J, et al: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58:641-652, 2009.
19. Schutz A, Hartig W, Wobus M, Grosche J, Wittekind Ch and Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch 446:421-429, 2005. (Pubitemid 40674850)
20. Chen X, Liao J, Lu Y, Duan X and Sun W: Activation of the PI3K/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells PANC-1. Pathol Oncol Res 17:257-261, 2011.
21. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 55:1584-1589, 2006. (Pubitemid 44327846)
22. Kaiser BK, Yim D, Chow IT, et al: Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447:482-486, 2007. (Pubitemid 46816733)
23. Najy AJ, Day KC and Day ML: The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 283:18393-18401, 2008.
24. Lucas N, Najy AJ and Day ML: The therapeutic potential of ADAM15. Curr Pharm Des 15:2311-2318, 2009.
25. Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008.
26. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447, 2006. (Pubitemid 46630982)
27. Yanagimoto H, Shiomi H, Satoi S, et al: A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24:795-801, 2010.
28. Koido S, Homma S, Takahara A, et al: Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011:267539, 2011.